RTS Life Science announces new headquarters
British company RTS Life Science, supplier of automated sample management and pharmaceutical testing systems, has announced a new US headquarters.
British company RTS Life Science, supplier of automated sample management and pharmaceutical testing systems, has announced a new US headquarters and the formation of ‘RTS Life Science LLC’. Following the acquisition earlier this year of Hatch Science, a Massachusetts based life science company, both products and services have now been successfully integrated into the Group.
With a US team of approximately 20 mechanical, electrical, software, sales and support staff and a design engineering and manufacturing facility, RTS is reported to now be able to provide sales, engineering and support services to its US client base of sample management, biobanking and pharmaceutical testing customers.
Gary Walsh, CEO of RTS commented. “Our strategy is to strengthen our capabilities in the US which has always represented a substantial part of our business. We now have an extended localized team and have fully integrated our US operations into the business.”
For further information regarding RTS Life Science or automation solutions for sample management, biobanking or pharmaceutical testing applications visit www.rts-group.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
